RU2018143809A3 - - Google Patents

Download PDF

Info

Publication number
RU2018143809A3
RU2018143809A3 RU2018143809A RU2018143809A RU2018143809A3 RU 2018143809 A3 RU2018143809 A3 RU 2018143809A3 RU 2018143809 A RU2018143809 A RU 2018143809A RU 2018143809 A RU2018143809 A RU 2018143809A RU 2018143809 A3 RU2018143809 A3 RU 2018143809A3
Authority
RU
Russia
Application number
RU2018143809A
Other languages
Russian (ru)
Other versions
RU2018143809A (ru
RU2763493C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018143809A publication Critical patent/RU2018143809A/ru
Publication of RU2018143809A3 publication Critical patent/RU2018143809A3/ru
Application granted granted Critical
Publication of RU2763493C2 publication Critical patent/RU2763493C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2018143809A 2016-05-12 2017-05-11 Способы лечения расстройств циркадного ритма сна RU2763493C2 (ru)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662335599P 2016-05-12 2016-05-12
US201662335611P 2016-05-12 2016-05-12
US62/335,611 2016-05-12
US62/335,599 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US62/413,976 2016-10-27
US201662414606P 2016-10-28 2016-10-28
US201662414599P 2016-10-28 2016-10-28
US62/414,606 2016-10-28
US62/414,599 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (3)

Publication Number Publication Date
RU2018143809A RU2018143809A (ru) 2020-06-15
RU2018143809A3 true RU2018143809A3 (https=) 2020-09-17
RU2763493C2 RU2763493C2 (ru) 2021-12-29

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018143809A RU2763493C2 (ru) 2016-05-12 2017-05-11 Способы лечения расстройств циркадного ритма сна

Country Status (16)

Country Link
US (2) US11096941B2 (https=)
EP (2) EP4056180A1 (https=)
JP (2) JP6888026B2 (https=)
KR (2) KR102511855B1 (https=)
CN (1) CN109640998A (https=)
AU (3) AU2017264871B2 (https=)
CA (1) CA3022068A1 (https=)
ES (1) ES2904625T3 (https=)
IL (2) IL291791B2 (https=)
MX (1) MX379318B (https=)
MY (1) MY199382A (https=)
RU (1) RU2763493C2 (https=)
SG (1) SG11201809527UA (https=)
TW (1) TWI795359B (https=)
WO (1) WO2017197160A1 (https=)
ZA (1) ZA201807903B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096941B2 (en) * 2016-05-12 2021-08-24 Eisai R&D Management Co.. Ltd. Methods of treating circadian rhythm sleep disorders
BR112021026291A2 (pt) * 2019-06-26 2022-03-03 Eisai R&D Man Co Ltd Lemborexant para tratar problemas de sono
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
JP7573015B2 (ja) * 2019-09-13 2024-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症治療用医薬組成物
JP2023506025A (ja) * 2019-12-11 2023-02-14 テバ チェコ インダストリーズ エス.アール.オー. レンボレキサントの固体形態
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
WO2023007320A1 (en) * 2021-07-26 2023-02-02 Eisai R&D Mangement Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
WO2024064897A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
CN121646412A (zh) 2023-08-08 2026-03-10 株式会社明治 昼夜节律的调整

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
US11096941B2 (en) * 2016-05-12 2021-08-24 Eisai R&D Management Co.. Ltd. Methods of treating circadian rhythm sleep disorders

Also Published As

Publication number Publication date
KR102511855B1 (ko) 2023-03-20
CA3022068A1 (en) 2017-11-16
BR112018073037A2 (pt) 2019-02-26
JP6888026B2 (ja) 2021-06-16
AU2025205336A1 (en) 2025-07-31
MX2018013663A (es) 2019-07-18
JP2019518732A (ja) 2019-07-04
JP2021120410A (ja) 2021-08-19
RU2018143809A (ru) 2020-06-15
MX379318B (es) 2025-03-10
US20200179382A1 (en) 2020-06-11
US11096941B2 (en) 2021-08-24
WO2017197160A1 (en) 2017-11-16
AU2023203418A1 (en) 2023-06-29
RU2763493C2 (ru) 2021-12-29
NZ748555A (en) 2025-06-27
IL291791B2 (en) 2025-09-01
IL262803B (en) 2022-05-01
SG11201809527UA (en) 2018-11-29
KR20190013820A (ko) 2019-02-11
CN109640998A (zh) 2019-04-16
EP3454859A1 (en) 2019-03-20
IL291791A (en) 2022-06-01
ZA201807903B (en) 2021-04-28
AU2017264871B2 (en) 2023-03-16
AU2017264871A1 (en) 2018-11-15
IL291791B1 (en) 2025-05-01
US20210353625A1 (en) 2021-11-18
IL262803A (en) 2018-12-31
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
EP4056180A1 (en) 2022-09-14
MY199382A (en) 2023-10-25
TWI795359B (zh) 2023-03-11
JP7150096B2 (ja) 2022-10-07
EP3454859B1 (en) 2021-12-01
ES2904625T3 (es) 2022-04-05

Similar Documents

Publication Publication Date Title
RU2018143809A3 (https=)
BR112019009263A2 (https=)
BR112019009262A2 (https=)
BR112019009373A2 (https=)
CN303538367S (https=)
CN303536212S (https=)
CN303661453S (https=)
CN303538541S (https=)
CN303538471S (https=)
CN303655676S (https=)
CN303538456S (https=)
CN303538295S (https=)
CN303640930S (https=)
CN303538165S (https=)
CN303635851S (https=)
CN303538059S (https=)
CN303634318S (https=)
CN303537999S (https=)
CN303537853S (https=)
CN303629665S (https=)
CN303537797S (https=)
CN303626030S (https=)
CN303616304S (https=)
CN303537770S (https=)
CN303611497S (https=)